VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 32,826 shares, a drop of 62.6% from the February 12th total of 87,870 shares. Based on an average daily volume of 94,910 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.3% of the company’s stock are sold short. Currently, 1.3% of the company’s stock are sold short. Based on an average daily volume of 94,910 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, VivoSim Labs presently has an average rating of “Sell”.

VivoSim Labs Stock Up 1.6%

Shares of NASDAQ VIVS opened at $1.90 on Wednesday. VivoSim Labs has a fifty-two week low of $1.41 and a fifty-two week high of $5.52. The business has a 50 day moving average price of $2.03 and a two-hundred day moving average price of $2.39. The firm has a market cap of $4.96 million, a PE ratio of -0.90 and a beta of 1.25.

VivoSim Labs (NASDAQ:VIVS) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.The business had revenue of $0.03 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is owned by institutional investors.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.